CiMUS Innopharma Open Innovation Day, Santiago de Compostela, Spain Stefan Senger (GlaxoSmithKline) gave a presentation: What is Open PHACTS and why would you care?
CiMUS Innopharma Open Innovation Day, Santiago de Compostela, Spain Stefan Senger (GlaxoSmithKline) View presentation
Understanding the knowledge management needs of phenotypic screening (Santiago de Compostela, Spain)
We are delighted to announce that the Open PHACTS project will be extendedfor 18 months until the end of February 2016. For the extension two new partners – Laboratorios Almirall S.A. and SciBite Limited – will join the consortium and GlaxoSmithKline (GSK) will act as coordinator.
(PDF) Cambridge, UK – The not-for-profit Open PHACTS Foundation announced its first three members today – GlaxoSmithKline, Janssen and Roche – who will steer the future of the successor organisation to the Innovative Medicines Initiative (IMI)- funded Open PHACTS project. The commitment by these global pharmaceutical industry members signifies a major…
14th Annual Drug Discovery Summit, Geneva, Switzerland Andrew Leach (GlaxoSmithKline) View presentation
14th Annual Drug Discovery Summit, Geneva, Switzerland Andrew Leach (GlaxoSmithKline) gave a presentation: Open PHACTS: Data integration for all
SMi Annual Advances and Progress in Drug Design 2013, London, UK Andrew Leach (GlaxoSmithKline) gave a presentation
The identification of proteins which could be potential targets for new pharmaceutical products is invaluable for the continued improvement people’s quality of life and expansion of available treatment options. In order to aid the discovery of new drug targets, predictions of every human gene likely to be exploitable by compounds…